Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Core Insights - Terns Pharmaceuticals has appointed Robert Azelby to its Board of Directors, bringing 25 years of strategic, operational, and commercial expertise in the biotechnology sector [1][2] - Carl Gordon is stepping down from the Board after over seven years of service, having played a foundational role in the company's development [1][2] Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases, including oncology and obesity [4] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [4] Leadership Experience - Robert Azelby has over 30 years of experience in the biopharmaceutical industry, having held leadership positions at Eliem Therapeutics, Alder BioPharmaceuticals, and Juno Therapeutics, among others [3] - His previous roles include serving as chief executive officer and various executive positions at Amgen, where he focused on oncology [3] Strategic Direction - The appointment of Mr. Azelby is expected to enhance Terns' strategic and operational leadership, particularly as the company prepares for late-stage studies of its lead oncology program, TERN-701, in chronic myeloid leukemia [2] - The company aims to advance its lead oncology and obesity programs towards significant clinical readouts later in the year [2]